![]() However, these examinations cannot be performed frequently due to radiation side effects ( 3). Imaging technology, including computed tomography (CT) or magnetic resonance imaging (MRI), can be used to measure the tumor size in follow-up patients. Earlier detection of tumor recurrence and monitoring of therapy outcome may give physicians more time for disease management. However, unsustainable clinical benefit was noted, and recurrence and therapy resistance are emerging as the major causes for limited clinical improvement. Advances in active agents and biomarker-driven treatment selection have improved outcomes in metastatic CRC patients. For most surgical CRC patients, tumor recurrence or metastasis is still a major challenge most recurrences occur within 2 years of surgery, and 90% by 5 years. It remains a major cause of cancer mortality and morbidity among men and women globally ( 1, 2). In conclusion, the present study demonstrated the association between dynamic changes in TCR diversity during chemotherapy and clinical outcomes as well as the potential utility of the TCR repertoire in predicting the prognosis of cancer treatment.Ĭolorectal cancer (CRC) is one of the most common cancers worldwide. TCR baseline diversity was also significantly associated with partial response (PR) status (odds ratio: 5.29, p = 0.04). Furthermore, compared with baseline TCR diversity, patients whose TCR diversity dropped considerably during therapy had better treatment responses, including lower CEA and CA19-9 levels and smaller tumor sizes. The diversity of TCR repertoires and CDR3 clonotypes decreased in most mCRC patients after therapy. We found that TCRα repertoires, TCRβ repertoires, and CDR3 clonotypes were altered in mCRC patients compared with healthy controls. Herein, we comprehensively profile 103 peripheral blood samples from 20 healthy controls and 16 CRC patients with a follow-up of 98 to 452 days to identify hypervariable rearrangements of the TCRα and TCRβ repertoires using high-throughput sequencing. In this study, we aimed to determine the characteristics and clinical significance of the TCR repertoire in patients with unresectable metastatic colorectal cancer (mCRC). The dynamic change in the T-cell receptor (TCR) repertoire might be a clinical parameter for monitoring treatment responses. The immune status of the cancer patient may affect the effectiveness of disease treatments. Despite advances in chemotherapy and targeted therapy, unsustainable clinical benefit was noted due to recurrence and therapy resistance. 12Department of Otolaryngology-Head and Neck Surgery, Chang Gung Memorial Hospital, Taoyuan, TaiwanĬolorectal cancer (CRC) is a major cause of cancer mortality and morbidity. ![]() 11Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Taoyuan, Taiwan.10Department of Neurosurgery, Lin-Kou Medical Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.9Department of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.8Division of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan.7Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |